Retatrutide Prescribed Online to Tennessee Residents
Medical Weight Loss Treatment in Tennessee
Retatrutide (LY3437943) is a 39-amino acid synthetic peptide and triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Currently in Phase 3 clinical trials (TRIUMPH program), it produced 24.2% average weight loss at 48 weeks in Phase 2 data — the highest weight reduction observed in any peptide trial to date. Listed by OmniRx for research-use only (RUO).
Key Benefits
- Triple receptor mechanism: GLP-1 + GIP + glucagon for amplified metabolic effect
- Phase 2 data shows 24.2% average weight loss at 48 weeks (12mg dose)
- ~58% hepatic fat reduction in Phase 2 sub-group analyses
- Elevated basal metabolic rate via glucagon receptor agonism
- Research-grade purity ≥98% with full CoA, HPLC, and MS documentation
Who is a Good Candidate?
Intended for laboratory researchers and pre-clinical study investigators studying triple receptor agonism, obesity mechanisms, hepatic metabolism, or GLP/GIP/glucagon signaling pathways. Listed for research-use only (RUO) — not for human therapeutic use.
Available for research use
Serving Tennessee
Tennessee stretches from the Great Smoky Mountains to the Mississippi River, with Nashville's healthcare industry at its heart. OmniRx Health serves the entire Volunteer State—music industry professionals in Nashville, logistics workers in Memphis, outdoor enthusiasts in the Smokies, and families in the small towns that make Tennessee special. Our telehealth platform brings Music City healthcare quality to every corner of the state.
OmniRx Health providers are licensed by the Tennessee Board of Medical Examiners for comprehensive telehealth services statewide.
Tennessee pharmacies in Nashville, Memphis, Knoxville, and throughout the state ensure prescription access with reliable delivery.
Tennessee's telehealth laws support virtual care delivery while ensuring patient safety and provider accountability.
Tennessee requires telehealth coverage for commercial insurers and has expanded TennCare virtual care benefits.
Frequently Asked Questions
- What is retatrutide and how does it work?
- Retatrutide (CAS 2381089-83-2) is a 39-amino acid synthetic peptide that simultaneously activates GLP-1, GIP, and glucagon receptors. This triple agonism produces coordinated appetite suppression (GLP-1), amplified insulin and fat-cell metabolism (GIP), and increased hepatic glucose output and resting energy expenditure (glucagon). It is currently in Phase 3 clinical trials and is available for research-use only (RUO).
- How does retatrutide compare to semaglutide and tirzepatide in research?
- Phase 2 data (NEJM, 2023) showed retatrutide at 12mg produced 24.2% average weight loss at 48 weeks, outperforming semaglutide (~15% at 68 weeks) and tirzepatide (~22% at 72 weeks) in their respective trials. Retatrutide adds glucagon receptor agonism — absent in both comparators — which appears to drive additional metabolic rate elevation and hepatic fat clearance.
- Is retatrutide available for human use?
- No. Retatrutide has not received FDA approval for any human therapeutic use. It is currently in Phase 3 (TRIUMPH) clinical trials and is listed by OmniRx strictly as a research-use only (RUO) compound for laboratory and pre-clinical research applications.
- Is telehealth legal in Tennessee?
- Yes, telehealth is legal in Tennessee. The state supports virtual healthcare delivery, allowing licensed providers to offer consultations, prescriptions, and ongoing care.
- Can East Tennessee residents access telehealth?
- Telehealth is ideal for East Tennessee, where mountain geography can make specialist access challenging. Our platform brings care to Knoxville, the Tri-Cities, and beyond.
- Does TennCare cover telehealth?
- Yes, TennCare covers telehealth services for eligible members. Tennessee has expanded virtual care coverage to improve healthcare access across the state.